Tradestie Institutional Equity Comparison Engine

MDCX vs EXYN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

MDCX Overall Edge

MDCX Captures Institutional Edge (2โ€“0 Pillars ยท 6โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Medicus Pharma Ltd. Common Stock (MDCX) driven by superior Growth & Margin, Momentum & Technical. Fundamentally, MDCX trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus EXYN at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, MDCX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against EXYN sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
MDCX N/M vs EXYN N/M Fwd P/E
Growth & Margin Winner MDCX
Op Margin 0.0% vs N/A ยท YoY +0.0% vs N/A
Momentum & Technical Winner MDCX
1Y -49.3% vs -70.0% ยท 52W Pos 23% vs 2%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
MDCX NASDAQ
Medicus Pharma Ltd. Common Stock
Pharmaceutical Preparations
$1.14
-2.16% 1D
Market Cap $3.1M
1M Return -56.68%
1Y Return -49.33%
Forward P/E N/M
Unified AI Score
49.2 / 100 HOLD
Tech 40.0 Fund 48.0 Flow 50.0 Mom 60.0
EXYN US Equity
EXYN
Institutional Equity
$1.56
-9.57% 1D
Market Cap N/A
1M Return -46.02%
1Y Return -70.0%
Forward P/E N/M
Unified AI Score
50.1 / 100 HOLD
Tech 53.0 Fund 52.0 Flow 50.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: MDCX -49.33% EXYN -70.0% Spread: +347.08 pp (MDCX Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
MDCX TTM Op. Margin: 0.0% EXYN TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MDCX vs EXYN. Trailing 12-month operating profitability (MDCX 0.0% vs EXYN N/A) and valuation multiples (MDCX N/M vs EXYN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: MDCX (6) vs EXYN (2)
Institutional Metric MDCX EXYN Criterion Row Winner
Market Capitalization Scale $3.1M N/A Larger Scale MDCX
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% N/A Higher Growth MDCX
Operating Margin (TTM) Profitability 0.0% N/A Higher Margin MDCX
Net Profit Margin Profitability 0.0% N/A Higher Margin MDCX
Return on Equity (ROE) Capital Efficiency -7446.1% N/A Higher ROE MDCX
52-Week Range Position Momentum 23% ($0โ€“$5) 2% ($1โ€“$7) Stronger Trend MDCX
Beta / 30D Volatility Risk Regime -0.28ฮฒ ยท 118% Vol 1.90ฮฒ ยท 85% Vol Lower Realized Risk EXYN
Unified Institutional Score Composite Signal 49.2 / 100 (HOLD) 50.1 / 100 (HOLD) Higher Composite EXYN

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full MDCX vs EXYN Buy Guide
MDCX UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live MDCX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
EXYN UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live EXYN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither MDCX nor EXYN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.